• Je něco špatně v tomto záznamu ?

The acute effects of methoxphenidine on behaviour and pharmacokinetics profile in animal model

K. Štefková-Mazochová, H. Danda, V. Mazoch, L. Olejníková-Ladislavová, K. Šíchová, N. Paškanová, M. Vágnerová, B. Jurásek, P. Ryšánek, M. Šíma, A. Šafanda, QH. Bui, M. Kuchař, T. Páleníček

. 2025 ; 137 (-) : 111285. [pub] 20250208

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009462

Methoxphenidine (MXP) is classified as a new psychoactive substance that has recently emerged on the illicit drug market. Understanding the pharmacological and behavioural profiles of newly emerging drugs is essential for a better understanding of their psychotropic effects and potential toxicity. Therefore, in this study, we investigated a broad range of effects of acute MXP administration: pharmacokinetics in the brain and serum; behaviour (open field and prepulse inhibition), systemic toxicity (lethal dose; LD 50), and histopathology changes in parenchymal organs of Wistar rats. MXP rapidly crossed the blood-brain barrier, reaching peak median concentrations in both serum and brain 30 min post-administration, followed by an elimination phase with a half-life of 2.15 h. Locomotor activity in the open field test displayed a dose-response effect at low to moderate doses (10-20 mg/kg MXP). At higher doses (40 mg/kg), locomotor activity decreased. All doses of MXP significantly disrupted prepulse inhibition and the effect was present during the onset of its action as well as 60 min after treatment. Additionally, MXP demonstrated moderate acute toxicity, with an estimated LD50 of 500 mg/kg when administered subcutaneously. In summary, MXP exhibited a profile similar to typical dissociative anesthetics, producing stimulant and anxiogenic effects at lower doses, sedative effects at higher doses, and disrupting sensorimotor gating. The accumulation of MXP in brain tissue is likely to contribute to acute intoxication in humans, potentially leading to negative experiences. Our findings highlight the potentially dangerous effects of recreational MXP use and underscore the risks of inducing serious adverse health outcomes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009462
003      
CZ-PrNML
005      
20250429134816.0
007      
ta
008      
250415e20250208enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.pnpbp.2025.111285 $2 doi
035    __
$a (PubMed)39929370
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Štefková-Mazochová, Kristýna $u Psychedelics Research Centre, National Institute of Mental Health, Topolová 748, Klecany 250 67, Czech Republic. Electronic address: kristyna.mazochova@nudz.cz
245    14
$a The acute effects of methoxphenidine on behaviour and pharmacokinetics profile in animal model / $c K. Štefková-Mazochová, H. Danda, V. Mazoch, L. Olejníková-Ladislavová, K. Šíchová, N. Paškanová, M. Vágnerová, B. Jurásek, P. Ryšánek, M. Šíma, A. Šafanda, QH. Bui, M. Kuchař, T. Páleníček
520    9_
$a Methoxphenidine (MXP) is classified as a new psychoactive substance that has recently emerged on the illicit drug market. Understanding the pharmacological and behavioural profiles of newly emerging drugs is essential for a better understanding of their psychotropic effects and potential toxicity. Therefore, in this study, we investigated a broad range of effects of acute MXP administration: pharmacokinetics in the brain and serum; behaviour (open field and prepulse inhibition), systemic toxicity (lethal dose; LD 50), and histopathology changes in parenchymal organs of Wistar rats. MXP rapidly crossed the blood-brain barrier, reaching peak median concentrations in both serum and brain 30 min post-administration, followed by an elimination phase with a half-life of 2.15 h. Locomotor activity in the open field test displayed a dose-response effect at low to moderate doses (10-20 mg/kg MXP). At higher doses (40 mg/kg), locomotor activity decreased. All doses of MXP significantly disrupted prepulse inhibition and the effect was present during the onset of its action as well as 60 min after treatment. Additionally, MXP demonstrated moderate acute toxicity, with an estimated LD50 of 500 mg/kg when administered subcutaneously. In summary, MXP exhibited a profile similar to typical dissociative anesthetics, producing stimulant and anxiogenic effects at lower doses, sedative effects at higher doses, and disrupting sensorimotor gating. The accumulation of MXP in brain tissue is likely to contribute to acute intoxication in humans, potentially leading to negative experiences. Our findings highlight the potentially dangerous effects of recreational MXP use and underscore the risks of inducing serious adverse health outcomes.
650    _2
$a zvířata $7 D000818
650    _2
$a mužské pohlaví $7 D008297
650    12
$a potkani Wistar $7 D017208
650    12
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a pohybová aktivita $x účinky léků $7 D009043
650    _2
$a prepulsní inhibice $x účinky léků $7 D065808
650    _2
$a mozek $x účinky léků $x metabolismus $7 D001921
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a piperidiny $x farmakokinetika $x farmakologie $7 D010880
650    _2
$a LD50 $7 D007928
650    _2
$a chování zvířat $x účinky léků $7 D001522
650    _2
$a test otevřeného pole $x účinky léků $7 D000082563
655    _2
$a časopisecké články $7 D016428
700    1_
$a Danda, Hynek $u Psychedelics Research Centre, National Institute of Mental Health, Topolová 748, Klecany 250 67, Czech Republic; 3(rd) Faculty of Medicine, Charles University, Ruská 87, Prague 10 100 00, Czech Republic
700    1_
$a Mazoch, Vladimír $u Psychedelics Research Centre, National Institute of Mental Health, Topolová 748, Klecany 250 67, Czech Republic
700    1_
$a Olejníková-Ladislavová, Lucie $u Psychedelics Research Centre, National Institute of Mental Health, Topolová 748, Klecany 250 67, Czech Republic
700    1_
$a Šíchová, Klára $u Psychedelics Research Centre, National Institute of Mental Health, Topolová 748, Klecany 250 67, Czech Republic
700    1_
$a Paškanová, Natálie $u Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology, Technická 5, Prague, 6, 166 28, Czech Republic
700    1_
$a Vágnerová, Magdaléna $u Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology, Technická 5, Prague, 6, 166 28, Czech Republic; Department of Analytical Chemistry, University of Chemistry and Technology, Technická 5, Prague 6 166 28, Czech Republic
700    1_
$a Jurásek, Bronislav $u Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology, Technická 5, Prague, 6, 166 28, Czech Republic
700    1_
$a Ryšánek, Pavel $u Institute of Pharmacology, 1(st) Faculty of Medicine, Charles University and General University Hospital in Prague, Albertov 4, Prague 2 128 00, Czech Republic
700    1_
$a Šíma, Martin $u Institute of Pharmacology, 1(st) Faculty of Medicine, Charles University and General University Hospital in Prague, Albertov 4, Prague 2 128 00, Czech Republic
700    1_
$a Šafanda, Adam $u Institute of Pathology, 1(st) Faculty of Medicine, Charles University, Studničkova 2, Prague 2 128 00, Czech Republic
700    1_
$a Bui, Quang Hiep $u Institute of Pathology, 1(st) Faculty of Medicine, Charles University, Studničkova 2, Prague 2 128 00, Czech Republic
700    1_
$a Kuchař, Martin $u Psychedelics Research Centre, National Institute of Mental Health, Topolová 748, Klecany 250 67, Czech Republic; Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology, Technická 5, Prague, 6, 166 28, Czech Republic
700    1_
$a Páleníček, Tomáš $u Psychedelics Research Centre, National Institute of Mental Health, Topolová 748, Klecany 250 67, Czech Republic; 3(rd) Faculty of Medicine, Charles University, Ruská 87, Prague 10 100 00, Czech Republic. Electronic address: tomas.palenicek@nudz.cz
773    0_
$w MED00003930 $t Progress in neuro-psychopharmacology & biological psychiatry $x 1878-4216 $g Roč. 137 (20250208), s. 111285
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39929370 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134812 $b ABA008
999    __
$a ok $b bmc $g 2311068 $s 1246543
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 137 $c - $d 111285 $e 20250208 $i 1878-4216 $m Progress in neuro-psychopharmacology & biological psychiatry $n Prog Neuropsychopharmacol Biol Psychiatry $x MED00003930
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...